# Northern Territory Point-of-Care Testing Program

Brooke Spaeth, NT POCT Program Coordinator Flinders University International Centre for Point-of-Care Testing


Dr Rodney Omond, NT POCT Program Clinical Advisor Senior RMP, Medical Director Low Acuity Medical Retrievals Primary Care Medical Unit, Top End Health Service



CQI Collaborative, Darwin 14 November 2017




### NT POCT Program – Impact & Growth



2008-2015 The Program started with 25 Remote Health Services in 2008 Expanded to 34 Services by 2015 (30 DoH & 4 ACCHS)

In 2015 approximately **1000 i-STAT tests** per month across Territory



2016 - 2018 After coroner's recommendation Every NT remote health service included in the Program 72 Remote Health Services 50 DoH (25 CA and 25 TE) + 22 ACCHS

In 2017 almost 3000 i-STAT tests per month across Territory

CG4+ = 10% Troponin I = 17% Chem8+ = 20% INR = 43%



## NT POCT Program – Workforce Capacity

Annual number of operators trained has <u>more than doubled</u> since expansion of program

- 2008 to 2015 = <u>125</u> staff trained on average
- 2016 = <u>328</u> staff trained
- 2017 = <u>322</u> staff trained (to October 2017)
- Total over 1400 staff trained since 2008







POC Training & Competency Assessment - involves a theoretical and practical assessment to <u>comply with best practice guidelines</u> for POCT in Australia\*

inder	International Centre for Point-of-Care Testing	TESTIN	G PROGRAM				
	i-STAT WRITTEN COM	PETENCY ASSE	SSMENT FOR NEW STAFF				
You	r Name:						
Con	tact email address:						
Hea	th Service Name/ Position:						
Pres	erred (4-digit) i-STAT Operator II	D:					
Pleas	e tick your selected answer(s).						
Q1.	Which of the following statements	is FALSE?					
Gen.	A cartridge must be warmed u	p to room temperature fo	r at least 5 minutes before use				
	<ul> <li>A cartridge can be returned to</li> <li>A cartridge can be stored at ro</li> </ul>	the fridge after it has bee or temperature for up to	n at room temperature 14 days				
Q2.	What is the preferred sample type	for an INR test?	Once complete submit				
	Venous whole blood in an ED	TA tube	to fax: 08 8201 7666 or				
	<ul> <li>Capillary sample, after wiping</li> <li>Capillary sample, using the first</li> </ul>		email: i-stat@flinders.edu.au				
220271		No	ç				
Q3.	What action do you take if your QC result is in the RED zone?						
	Continue patient testing						
	<ul> <li>Stop testing and call the Flinders iCPOCT unit to discuss results and troubleshooting</li> </ul>						
Q4.	What is the preferred patient sample type for a test on the Chem8+ cartridge?						
	<ul> <li>Venous whole blood in an EDTA (purple top) collection tube</li> <li>Venous whole blood in a lithium heparin (green top) collection tube</li> </ul>						
	Capillary sample, using the first drop						
	Removing the needle & loadin	g directly from the syring	Ð				
Q5.	A Troponin I test was performed on a patient suspected of having a cardiac event. The result						
	obtained was 0.09ng/mL. This result is: Clearly negative, the person has not had a cardiac event						
	<ul> <li>Clearly positive, and should be reported to the doctor immediately</li> </ul>						
	Indeterminate', so the patient needs to have their troponin I tested serially						
Q6.	Which of the following statements						
	<ul> <li>A cartridge can be removed from the i-STAT when it is turned OFF</li> <li>A cartridge can be removed from the i-STAT ONLY when "Remove Cartridge" is visible</li> </ul>						
	on the screen						
	Both of the above						
Q7.	What is the operational temperature range of the i-STAT device?						
	□ 16 to 30 °C □ 1 to 50 °C						
	Any temperature, there is no operational temperature range for the i-STAT device						
Q8.	When performing the INR QC test, once the activator liquid is added to the powder how long should						
	the solution be mixed for?						
	30 seconds						

<image>



Flinders University International Centre for Point-of-Care Testing

\*Badrick T, Badman S, Burnet L, Demediuk N, Faoagali J, Harman P, Griffen A, Harrison M, Martin C, McKenzie P, Shephard M, Tirimaaco R, Wale J, Stewart P, Whiley M. 2015. Guidelines for Point of Care Testing. (First edition 2015). NPAAC Best practice guidelines. Australian Government Department of Health, Canberra, Australia.

Testing both Quality Control (on every i-STAT device) and External Quality Assurance Testing (at selected hubs) <u>complies with National POCT guidelines</u>\*

Analyte	n	Target	i-STAT QC Mean	i-STAT QC CV%	Lab Median CV%
Sodium	233	122.0	121.5	0.6%	0.9%^
Potassium	233	2.9	2.9	0.8%	1.4%^
Chloride	235	72	73	1.2%	1.2%^
Glucose	231	15.0	15.1	1.0%	2.1%^
Urea	233	19.3	19.3	2.6%	2.5%^
Creatinine	234	335.5	336.8	2.9%	2.7%^
рН	230	7.04	7.05	0.2%	1.4%*
Lactate	229	7.1	6.9	2.4%	4.6%*
Troponin I	196	0.34	0.31	7.0%	7.7%^

#### Table – Representative example of Quality Control testing results for the i-STAT



\*Badrick T, Badman S, Burnet L, Demediuk N, Faoagali J, Harman P, Griffen A, Harrison M, Martin C, McKenzie P, Shephard M, Tirimaaco R, Wale J, Stewart P, Whiley M. 2015. Guidelines for Point of Care Testing. (First edition 2015). NPAAC Best practice guidelines. Australian Government Department of Health, Canberra, Australia.



POC connectivity enables surveillance of all i-STAT tests conducted across the Territory, which allows monitoring and <u>reduces wastage</u>/errors + <u>improves patient safety</u>.

Date - Time	Patient ID	Location	Operator ID	Serial Number	Panel	Received Date - Time
10/03/16 10:49:31	0534342	Milingimbi	2009	309806	PT	10/03/16 11:03:31
10/03/16 11:15:00	21091968	Yulara	8245	330802	CHEM8+	10/03/16 11:17:00
10/03/16 11:18:41	0295984	Oenpelli	3802	327117	PT	10/03/16 11:44:41
10/03/16 11:36:33	0616153	Engawala	8055	373502	PT	10/03/16 11:52:33
10/03/16 12:34:04	17071950	Balgo KAMSC	3569	359354	PT	10/03/16 12:39:04
10/03/16 10:24:21	0530656	Gapuwiyak	2341	309814	PT	10/03/16 12:39:21
10/03/16 11:08:32	0654168	Titree	7086	309813	PT	10/03/16 13:23:32
10/03/16 13:19:12	0450091	Oenpelli	7952	327117	cTnl	10/03/16 13:30:12
10/03/16 13:04:19	0450091	Oenpelli	7952	327117	CHEM8+	10/03/16 13:30:19
10/03/16 13:51:18	0438176	Angurugu	8095	305652	PT	10/03/16 13:56:18
10/03/16 14:01:18	301066	Titree	7086	309813	CHEM8+	10/03/16 14:06:18
10/03/16 13:55:46	301066	Titree	7086	309813	CG4+	10/03/16 14:06:46
10/03/16 14:36:28	0288754	Oenpelli	7903	327117	PT	10/03/16 14:42:28
10/03/16 14:20:07	0036673	Palumpa	3632	375616	PT	10/03/16 14:48:07
10/03/16 14:28:18	0204305	Palumpa	3632	375616	PT	10/03/16 14:48:18
10/03/16 12:49:09	0503647	Numbulwar	2943	309803	cTnl	10/03/16 15:10:09
10/03/16 12:44:28	0503647	Numbulwar	7790	309803	CHEM8+	10/03/16 15:10:28
10/03/16 13:49:30	0503647	Numbulwar	2943	309803	CG4+	10/03/16 15:10:30
10/03/16 13:06:40	0507575	Numbulwar	2943	309803	cTnl	10/03/16 15:10:40

Method: i-STAT


•

Viewer last updated: 31Oct2017 15:22

Total results in viewer: 35554



Monthly Feedback Reports to HCMs and DMs provides <u>CQI recommendations</u> to each health service on patient testing, training, errors, QC and QA testing + assists with ordering i-STAT stock (reduces wastage)





#### **Publications:**

- Shephard MS, Spaeth B, Mazzachi BC, Auld M, Schatz S, Loudon J, Rigby J, Daniel V, 'Design, **implementation** and initial assessment of the Northern Territory Point-of-Care Testing Program', *Australian Journal of Rural Health*, 2012; 20(1):16-21.
- Shephard MDS, Spaeth BA, Mazzachi BC, Auld M, Schatz S, Lingwood A, Loudon J, Rigby J, Daniel V, 'Toward Sustainable Point-of-Care Testing in Remote Australia – the Northern Territory i-STAT Point-of-Care Testing Program', *Point of Care*, 2014; 13(1): 6-11.
- Spaeth BA, Shephard MDS, Schatz S, 'Point-of-care testing for haemoglobin A1c in remote Australian Indigenous communities **improves timeliness** of diabetes care', *Rural and Remote Health*, 2014; 14: 2849.
- Spaeth BA, Shephard MDS, 'Clinical and Operational Benefits of International Normalised Ratio Point-of-Care Testing in Remote Indigenous Communities in Australia's Northern Territory', *Point of Care*, 2016; 15(1): 30–34.
- Spaeth B, Shephard MDS, Auld M, Omond R, 'Immediate pathology results now available for all remote Northern Territorians', Proceedings of the 14th National Rural Health Conference, editor Leanne Coleman, Cairns, Queensland, 26-29 March 2017. Canberra: National Rural Health Alliance, 2017.
- Spaeth B, Shephard MDS, Omond R, '**Clinical Application** of Point-of-Care Testing in the Remote Primary Health Care Setting', *Quality in Primary Care*, 2016; 25(3): 164-175.
- Spaeth B, Kaambwa B, Shephard MDS, Omond R, 'Economic Assessment of Pointof-Care Testing in the Remote Primary Health Care Setting', submitted to *BMC Health Services Research* 2017.

Quality in Primary Care (2017) 25 (3): 164-175

© 2017 Insight Medical Publishing Group

#### **Research Article**

#### Clinical Application of Point-of-Care Testing in the Remote Primary Health Care Setting

#### Brooke A Spaeth

Flinders University International Centre for Point-of-Care Testing, Flinders University, Bedford Park, South Australia, Australia Mark DS Shephard

Rinders University International Centre for Point-of-Care Testing, Flinders University, Bedford Park, South Australia, Australia Rodney Omond

Primary Health Care Branch Medical Unit, Top End Health Service, Northern Territory, Casuarina Plaza, Casuarina, Australia

#### ABSTRACT

Australia

Background: Point-6-care testing (POCT) enables immediate pathology results to be used for timely elimital action during the patient presentation. While many benefits of POCT for chronic and infectious conditions have been welldocumented, lew studies have focused on the clinical benefits of POCT for acutely ill patients in remote communities. Amis: To determine the clinical effectiveness of POCT is a

decision support tool for triaging acutely ill patients in remote

who did or did not require evacuation (as a result of POCT

Methods: An audit examined three acute medical

Results: 200 patient cases met the selection enterin for the presentation typess OI 147 patients with chest yani. 126 patients, were not evacuated due to on-anite POCT for troponin 1; from this latter group, 48 patients (39%) would have been evacuated if POCT wan an wallable. Three of severa patients (49%) identified with nor-STI-MI through POCT would not have been evacuated if POCT was normaliable. OI 17 patients evacuated with seate renal disease, foru (24%) had initial potassium results >6.5 mmOL, 201 Iour everved evaluation gates and the evacuated and and serial POCT. With decreased potassium levels at evacuation. All 10 patients evacuated with neuted diarrhooa at evacuation. All 10 patients evacuated with neuted diarrhooa

presentations (patients with neute chest pair, patients with neate exacerbance of renal failure due to a mised dailysis session(s) and patients with neute distributions with a size distribution of the Northern Territory where PGCT and a start of a size of the neat for exacution to a territary hespital routinely available. The main clinical cuscome was the percentage (%) of patients with each acute presentation the community and be stabilised.

Keywords: Point-of-care testing: Acute care; Remote; Rural; Primary health care; Patient safety

#### How this fits in with quality in primary care? What do we know?

Current literature indicates that point-of-care testing (POCT) is able to provide improved detection and management of patients with chronic and infectious disease. Little information is available on the clinical benefits of POCT when used for acute care, naricalized in the remove health setting.

#### What does this paper add?

This study provides quantitative evidence and illustrative case studies which highlight the clinical benefits of being able to conduct POCT for acute medical conditions in remote primary care.

For Indigenous Australians, there are also cultural benefits of acute POCT through stabilising a patient's clinical condition on-site and thereby enabling them to remain in community.

#### Background

In Australia, general health status and life expectancy of people living in rural and remote areas is significantly lower than those in neuropolitan or ubhan locations (1) While there are many well-documented reasons for these disparities, ogcographical distance from the services and resources available in large metropolism centres is a major factor [2]. For pathology services, most laboratories are generally located in large

metropolician centres close to a tertisey hospital. People living in these centres can generally expect to receive their pathology results on the same day or for emergency care within the hour [3]. For those living in rural or remote losations, the wait time for pathology results can range anywhere from 24 hours to 2 weeks [4,5]. In the case of an emergency a common option is to evacuate the patient to the nearest hospital to have the pathology tests conducted to assist in determining the patient 3 diagnosis.



### **NT POCT Program – Clinical & Cost Effectiveness**

**Research Project Title**: Point-of-Care Testing for Better Management of Acutely III Remote Patients (Sponsored by Emergency Medicine Foundation -EMF)

- Investigated clinical and cost effectiveness of using the i-STAT as a decision support tool for triaging acutely ill patients
- Focussed on 3 common acute clinical presentations in 200 patients (chest pain [n=147], missed dialysis [n=28] and acute diarrhoea [n=25])
- 6 remote health centres (small, medium, large) with access to POCT
- POCT enabled early diagnosis and treatment for those appropriately evacuated (n=21)
- Access to POCT resulted in the prevention of 60 medical evacuations
- Health Economist extrapolated results to provide Territory-wide estimates of cost savings
- Territory-wide **cost saving of \$20.93 million per annum for NT health system** through prevention of unnecessary medical evacuations for just these 3 presentations.
- POCT also delivered **improved clinical outcomes for acutely ill patients** in remote communities.





## i-STAT – Use in Duty RMP Consultations

### **Priorities for Duty RMP consultations**

- Problem determines order
- Clinical Observations T, P, RR, BP
- Other clinical information
- POCT information
- ECG, CXR
- Ring Duty RMP







- Siemens DCA Vantage POCT device
- HbA1c for diabetes management & diagnosis
- Urine ACR for detection of <u>early kidney disease</u>
- Results in < 7 minutes
- Primarily AHP/AHW trained as operators
- Medicare Rebates Available
- Significant improvements in diabetes control <u>if integrated</u> into clinical practice\*








Flinders University International Centre for Point-of-Care Testing

\*Spaeth BA, Shephard MDS, Schatz S, 'Point-of-care testing for haemoglobin A1c in remote Australian Indigenous communities **improves timeliness** of diabetes care', *Rural and Remote Health*, 2014; 14: 2849.

## **NT POCT Program – Future Directions**

#### HemoCue WBC DIFF

- Total and 5-part differential white cell count (Lymphocytes, Neutrophils, Monocytes, Basophils, Eosinophils)
- Result in < 5minutes
- Analytically sound in remote environment\*
- 2017 evaluation in 13 remote health services in NT to research <u>clinical</u>, <u>operational and cost</u> <u>effectiveness</u>



Julanimav

Belvuen



**Flinders University** International Centre for Point-of-Care Testing

Lake Nash

Maningrida

Reference: Spaeth BA, Shephard MDS, McCormack B, Sinclair G, 'Evaluation of HemoCue white blood cell differential counter at a remote health centre in Australia's Northern Territory', Pathology, 2015; 47(1): 91-95.

## HemoCue WBC DIFF Trial Results

#### **Clinical Effectiveness / Patient Safety:**

- Sepsis
- Respiratory infections
- Appendicitis
- Fever + undifferentiated symptoms
- Monitoring Clozapine medication

#### **Cost benefit:**

 Cost savings through prevented evacuations = \$500,000 across 13 sites over 6 month period

#### **Operational benefits:**

- High satisfaction / ease of use
- 37% of FBE pathology reports returned with WCC not reliable / not reported (+ cost benefit)



Quote from Rural Medical Practitioner: "[The HemoCue WBC DIFF] is a piece of equipment that should be in every remote community."



## **NT POCT Program – Future Directions**

#### HemoCue Hb 201+

- Currently no training or quality structure in place (as for the i-STAT)
- Concerns raised regarding reliability of Hb results
- No clinical protocol available to assist with results that do not fit clinical picture
- Confusion between test methods available (HemoCue, i-STAT, Pronto, laboratory)



# Thank you to.... all the members of NT POCT Program Management Team

### NT DoH

- Dr Rodney Omond
- Dana Dabrowska
- Malcolm Auld
- Tina Quirk
- Casey Vandermeer
- Steve Schatz
- + many other past members

### AMSANT

- Margie Cotter

### **Flinders ICPOCT**

- Prof Mark Shephard (chair)
- Brooke Spaeth
- Lauren Duckworth
- Bek Milloss
- Janet Richards



## **Discussion and Questions?**

### i-STAT

- Operationally effective
- Cost benefit to NT
- Improved patient safety
- Anything else to investigate?

### QAAMS / DCA Vantage

- How to better incorporate into routine clinical practice?
- Issues with current use?

### **Other POC tests?**

- HemoCue WBC DIFF
- HemoCue Hb 201
- Others e.g. Syphilis, Strep A, Influenza, CRP, Lipids.....

## Thank you

